Press "Enter" to skip to content

Retinoblastoma Treatment Market Outlook 2019 | Shows Industry Overview, Size, Share, Remarkable Growth Factors, Types, and Applications Forecast to 2024


The “Retinoblastoma Treatment Market” research report 2019-2024 delivers comprehensive information and valuable insights about the Retinoblastoma Treatment industry. The information available in the Retinoblastoma Treatment market report is not only based on the facts but also on the case studies, which analysts have included to convey appropriate information to the clients in a well-versed manner. Retinoblastoma Treatment market report includes valuable information to assist new entrants, as well as established players, to understand the prevailing trends in the market.

Some Companies Are Covered in the Retinoblastoma Treatment Market:

  • Baxter International Inc.
  • Bristol
  • Myers Squibb Company
  • Cadila Pharmaceuticals
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co.
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.

    Get a Sample Copy of the Report –

    Market Overview:

  • Global Retinoblastoma Treatment market was valued at USD 2297.13 million in 2018, and is estimated to be valued at USD 3001.78 million in 2024, witnessing a CAGR of 4.56%. certain factors that are driving the market growth include remission and the chance of recurrence, and increasing public awareness.
  • Recurrent retinoblastoma occurs, when cancer comes back after it has been treated and diagnosed. Both extraocular and intraocular retinoblastoma might have probable chances of remittance.
  • Generally, the likelihood of relapse and formation of secondary tumors increases with the genetic nature of the disease. Patients with non-hereditary or sporadic retinoblastoma are not as susceptible to relapse, as hereditary ones. Although, the cure rate for retinoblastoma is quite high, the exact cure rate is dependent on the extent of the disease and chances of recurrence. The increasing number of treatment procedures drive the retinoblastoma treatment market.
  • In addition, improving awareness about retinoblastoma is a worthwhile goal, and any eye complaint merits careful attention from all nursing and medical personnel. Improving awareness regarding retinoblastoma is especially important in developing countries, as the incidences of eye cancer are increasing, and many children die undiagnosed or have advanced disease at presentation, due to delay in referral to an oncology centre. Retinoblastoma educational and public awareness campaigns have been shown to increase referrals, decrease rates of advanced disease, and improve outcomes in low and middle-income countries.
  • However, side effects of retinoblastoma surgery, radiation therapy to the head and certain chemotherapy drugs, such as cisplatin and carboplatin (Paraplatin, Paraplatin AQ), may cause hearing loss when they are given to very young children. The other eye problems include difficulty in judging distance between objects and difficulty seeing to the side (peripheral vision). Eye problems can also lead to changes in balance.

    Scope of the Report:

  • Retinoblastoma is the most common cancer among children, which starts in the retina. It generally develops before the age of 5. One out of three children with retinoblastoma develops cancer in both eyes. The most common symptom of retinoblastoma is a visible whiteness in the pupil, called cat’s eye reflex or leukocoria.

    Reasons for Buying Retinoblastoma Treatment Market Report:

    • This report provides pin-point analysis for changing competitive dynamics
    • It provides a forward looking perspective on different factors driving or restraining market growth
    • It provides a five-year forecast assessed on the basis of how the market is predicted to grow
    • It helps in understanding the key product segments and their future
    • It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
    • It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

    For More Information or Query or Customization Before Buying, Visit at –

    Key Market Trends:

    Non-hereditary Retinoblastoma is Expected to hold its Highest Market Share in the Retinoblastoma Type Segment

    In the Retinoblastoma type segment of the Retinoblastoma treatment market, the non-hereditary retinoblastoma (NHR) is expected to have the largest market size and is likely to witness a CAGR of 3.82% in the forecast period.

    Non-hereditary retinoblastoma (NHR), also known as sporadic retinoblastoma, is the more prevalent form of retinoblastoma. According to the American Cancer Society, 67% of reported cases (in the United States) of retinoblastoma in pediatrics are non-hereditary or sporadic.

    The NHR is mostly a pediatric disease, and according to the American Cancer Society, the survival rates post diagnosis is approximately 90%. According to the Union for International Cancer Control, the average age-adjusted incidence rate of retinoblastoma in the United States and Europe is 2-5/106 children (approximately one in 14,000 – 18,000 live births).

    The market for NHR is expected to grow tremendously over the forecast period, primarily due to the higher incidence rate, when compared to hereditary retinoblastoma. Additionally, factors, like high survival rates post diagnosis in developed regions, like the United States, are likely to add to the global market growth.

    Asia-Pacific Dominates the Market and Expected to do Same in the Forecast Period

    Asia-Pacific currently dominates the market for Retinoblastoma Treatment and is expected to continue its strong hold for a few more years. This region is expected to increase its market share in the future owing to the fact that, retinoblastoma (Rb) is the most common primary intraocular malignancy of infancy and childhood, and seriously endangers the vision and life of children.

    According to the United Nations Survey in 2016, China was only second to that in India, in the prevalence of Rb in APAC countries. Similarly, according to the Japanese Journal of Ophthalmology, in 2018, the average occurrence frequency for retinoblastoma was 1:16,823 births/year and at diagnosis, 89.0% of the patients were aged younger than 3 years and 41.0% were aged younger than 1 year.

    Furthermore, in countries like India, current treatment modalities of systemic chemotherapy and focal treatment have contributed significantly to disability limitation and patient survival and there is less knowledge on the genetics of the retinoblastoma gene and its protein, and there is potential for developing targeted molecular therapies.

    Retinoblastoma Treatment Market Report Provides Comprehensive Analysis of:

    • Functional market industry outline
    • Up and downstream industry examination
    • Channels and propositions believability
    • Market challenge by key players
    • Enhancement suggestions examination

    Purchase this Report (Price 4250 USD for single user license) –

    Report Highlights:

    • Market Dynamics – Drivers, Restraints, and Opportunities
    • Market Segmentation – Types, Applications, Regions, and Technology
    • Market Trends
    • Competitive Landscape
    • SWOT Analysis and Porter’s Five Forces Analysis

    Detailed TOC of Retinoblastoma Treatment Market Report 2019-2024:

    1.1 Study Deliverables
    1.2 Study Assumptions
    1.3 Scope of the Study



    4.1 Market Overview
    4.2 Market Drivers
    4.2.1 Remission and the Chance of Recurrence
    4.2.2 Increasing Public Awareness
    4.3 Market Restraints
    4.3.1 Small Patient Pool
    4.3.2 Side Effects of Retinoblastoma Surgery
    4.4 Porter’s Five Force Analysis
    4.4.1 Threat of New Entrants
    4.4.2 Bargaining Power of Buyers/Consumers
    4.4.3 Bargaining Power of Suppliers
    4.4.4 Threat of Substitute Products
    4.4.5 Intensity of Competitive Rivalry

    5.1 By Treatment Type
    5.1.1 Surgery
    5.1.2 Radiation therapy
    5.1.3 Laser Therapy (Photocoagulation)
    5.1.4 Cryotherapy
    5.1.5 Thermotherapy
    5.1.6 Chemotherapy Carboplatin Cisplatin Vincristine Etoposide Cyclophosphamide Topotecan Doxorubicin Cyclosporine Melphalan
    5.1.7 Opthalmic Artery Infusion Chemotherapy
    5.1.8 High-dose Chemotherapy and Stem Cell Transplant
    5.2 By Type of Retinoblastoma
    5.2.1 Non-hereditary Retinoblastoma
    5.2.2 Hereditary Retinoblastoma
    5.3 By Type of Staging
    5.3.1 Intraocular Retinoblastoma
    5.3.2 Extraocular Retinoblastoma
    5.4 Geography
    5.4.1 North America US Canada Mexico
    5.4.2 Europe Germany UK France Italy Spain Rest of Europe
    5.4.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
    5.4.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
    5.4.5 South America Brazil Argentina Rest of South America

    6.1 Company Profiles
    6.1.1 Baxter International Inc.
    6.1.2 Bristol-Myers Squibb Company
    6.1.3 Cadila Pharmaceuticals
    6.1.4 GlaxoSmithKline plc
    6.1.5 Johnson & Johnson
    6.1.6 Merck & Co.
    6.1.7 Novartis AG
    6.1.8 Pfizer Inc.
    6.1.9 Teva Pharmaceutical Industries Ltd.



    Contact Us:

    Name: Ajay More

    Phone: US +14242530807/ UK +44 20 3239 8187

    Email: [email protected]

    Our Other Reports:

    Anesthetic Market Share, Size 2019 Developing Rapidly with Recent Trends, Development, Revenue, Demand and Forecast to 2024 | Says Industryresearch.Biz

    Testosterone Gel Market 2019 Industry Size, Trends, Global Growth, Recent Developments and Latest Technology, Forecast Research Report 2023

    Global Rock Sports Protection Products Market 2019 – Industry Analysis by Top Key Players, Key Countries, Market Size & Share, Growth Rate Forecast to 2023

    Meal Replacement Powder Market Segmentation 2018-2023 Covers Price, Sales, Revenue, Growth Rate Details by Regions, Types, and Applications

  • Be First to Comment

    Leave a Reply

    Your email address will not be published. Required fields are marked *